Despite recent progress in treating lung cancer, it remains the leading cause of cancer death in the U.S. as of 2019. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for 84% of diagnoses.
People affected by this disease may have a reason to feel more optimistic about available treatments. A new treatment option that harnesses the body’s immune system is now available for certain patients with advanced NSCLC whose cancer tests positive for PD-L1. Click here for more information.
